disappoint quarter sell-off
updat model follow compani result
disappoint miss revenu cash flow estim
view magnitud sell-off overdon said take
conserv stanc revenu growth lower pt
stock bounc back meaning believ investor may need
see quarter meaning higher revenu cash flow impli
manag guidanc full year unchang metric
look forward updat strateg review indic
near complet believ investor expect low front
view mani compani sharehold friendli
report ep consensu
revenu came estim slightli soft rel
myl expect due lower sale europ vs model
impact temporari busi disrupt due serial modestli
lower sale north america higher gross margin lower
oper expens drove upsid ep flow op
surprisingli low vs call plan
invest work capit support launch maintain
adjust free cash flow target
takeaway quarter
view key takeaway describ continu stabil
respect price us gener market manag note
busi disrupt europ behind compani continu
anticip mid-single-digit growth help back-end weight
launch cash flow surpris indic
expect necessari support launch view cash flow
full year chang
lower revenu revenu
base conserv assumpt europ
north america partial off-set higher sale gadvair note
sale estim continu reflect ramp come quarter driven
new product consist compani expect difficult
predict new ep ep
tr target
interest
revenu
page
interest
revenu
page
rest world
rest world
revenu
rest world
page
rest world
rest world
revenu
rest world
page
develop manufactur market gener brand gener biosimilar brand
drug over-the-counter product countri myl north america busi primarili focus
gener drug europ row segment focus brand over-the-counter product
compani establish broad biosimilar portfolio collabor biocon
start point see stock depress valuat financi expect
lower enough believ stock outperform despit
challeng environ base divers global busi larg pipelin includ biosimilar
addit recent launch gadvair biosimilar neulasta gain traction help
creat visibl difficult fight investor percept compani
particularli sharehold friendli hope on-going strateg review could help unlock
valu manag indic review near complet rate share buy
valuat risk
pt assum stock trade ebitda support
risk rate price target includ increas competit intens gener greater price
pressur us europ area delay approv quality/manufactur issu fine
relat opioid litig investig gener price collus disappoint capit
gregg gilbert herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
